ANDA 200104, held by Aiping Pharm Inc. Warfarin Sodium.
As of Nov 16, 2026, ANDA 200104 (Warfarin Sodium), held by Aiping Pharm Inc, was first approved by FDA on Jun 27, 2013, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 27, 2013 | Original application | Approved | None posted |
| Warfarin Sodium1MG · tablet;oral | Warfarin Sodium | Discontinued |
| Warfarin Sodium2MG · tablet;oral | Warfarin Sodium | Discontinued |
| Warfarin Sodium2.5MG · tablet;oral | Warfarin Sodium | Discontinued |
| Warfarin Sodium3MG · tablet;oral | Warfarin Sodium | Discontinued |
| Warfarin Sodium4MG · tablet;oral | Warfarin Sodium | Discontinued |
| Warfarin Sodium5MG · tablet;oral | Warfarin Sodium | Discontinued |
| Warfarin Sodium6MG · tablet;oral | Warfarin Sodium | Discontinued |
| Warfarin Sodium7.5MG · tablet;oral | Warfarin Sodium | Discontinued |
| Warfarin Sodium10MG · tablet;oral | Warfarin Sodium | Discontinued |
| Nov 14, 2019 | Supplement 1Labeling · Standard review | Approved | None posted |
| Nov 14, 2019 | Supplement 2Labeling · Standard review | Approved | None posted |
| Nov 14, 2019 | Supplement 4Labeling · Standard review | Approved | None posted |
| Nov 14, 2019 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jun 27, 2013 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters